FrancophonIA/ELRC3.0 huggingface dataset:
English: At any time during or after your treatment, tell your doctor or nurse immediately if you: experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion.
Croatian: U bilo kojem trenutku za vrijeme ili nakon liječenja ovim lijekom, odmah obavijestite svog liječnika ili medicinsku sestru ako: vam se pojavi zamagljen vid, gubitak vida ili dvostruka slika, poteškoće u govoru, slabost u ruci ili nozi, promjene u načinu hoda ili problemi s ravnotežom, trajna utrnulost, smanjen osjet ili gubitak osjeta, gubitak pamćenja ili smetenost.
English: If you feel drowsy, which may occur due to a low number of red blood cells caused by LITAK treatment, or dizzy, you should not drive or use machines.
Croatian: Ako osjetite pospanost, koja nastaje zbog sniženja broja crvenih krvnih stanica prouzročenog liječenjem lijekom LITAK, ili omaglicu, ne smijete upravljati vozilima i strojevima.
English: Cladribine is contraindicated in pregnancy.
Croatian: Kladribin je kontraindiciran tijekom trudnoće.
English: For severity, please see text below the table.
Croatian: Za ozbiljnost navedenih nuspojava vidjeti tekst ispod tablice.
English: It affects the growth of malignant (cancerous) white blood cells which play a role in hairy cell leukaemia.
Croatian: Utječe na rast zloćudnih (stanica raka) bijelih krvnih stanica koje imaju ulogu u leukemiji vlasastih stanica.
English: LITAK is a cytotoxic and should therefore be handled with caution.
Croatian: LITAK je citotoksičan lijek i stoga njime treba oprezno rukovati.
English: Paediatric population LITAK is contraindicated in patients less than 18 years of age (see section 4.3).
Croatian: Pedijatrijska populacija LITAK je kontraindiciran u bolesnika mlađih od 18 godina (vidjeti dio 4.3).
English: Intracellular concentration of cladribine exceeds its plasma concentration by 128 to 375 times.
Croatian: Unutarstanična koncentracija kladribina veća je od koncentracije u plazmi 128 do 375 puta.
English: Cladribine induces a severe and prolonged reduction of CD4+ and CD8+ T-lymphocytes.
Croatian: Kladribin izaziva teško i dugotrajno smanjenje broja CD4 i CD8 T limfocita.
English: The recommended daily dose is 0.14 mg per kg body weight for five consecutive days (single treatment course).
Croatian: Preporučena dnevna doza je 0,14 mg po kg tjelesne težine tijekom pet uzastopnih dana (jedna kura liječenja).
English: In case certain adverse reactions with a potential impact on performance occur (e.g. dizziness, very common, or drowsiness, which may occur due to anaemia, which is very common), patients should be advised not to drive or use machines.
Croatian: U slučaju pojave određenih nuspojava koje bi mogle utjecati na sposobnosti (npr. omaglica, vrlo često, ili pospanost, koje mogu nastati zbog anemije, koja je vrlo česta), bolesnicima treba savjetovati da ne upravljaju vozilima i ne rade sa strojevima.
English: Very rare: amyloidosis
Croatian: Vrlo rijetko: amiloidoza
English: If you have any question with regard to giving the injection, please ask your doctor or nurse for help.
Croatian: Imate li pitanja u pogledu davanja injekcije, obratite se svome liječniku ili medicinskoj sestri za pomoć.
English: In case of fever related to infections or agranulocytosis, an antibiotic treatment is indicated.
Croatian: U slučaju vrućice povezane s infekcijom ili agranulocitozom treba primijeniti antibiotsko liječenje.
English: The recommended dose is directly withdrawn by a syringe and injected as a subcutaneous bolus injection without dilution.
Croatian: Preporučena doza izravno se navuče u štrcaljku i injicira kao supkutana bolus injekcija bez razrjeđivanja.
English: Cladribine is unlikely to cause alopecia; mild and transient alopecia for a few days was observed in 4/523 patients during the treatment, but could not clearly be associated with cladribine.
Croatian: Mala je vjerojatnost pojave alopecije; blaga i prolazna alopecija tijekom nekoliko dana primijećena je u 4/523 bolesnika tijekom liječenja, ali nije bila dovedena u jasnu vezu s kladribinom.
English: Clinical experience is very limited and safety of LITAK in these patients is not well established (see sections 4.3 and 5.2).
Croatian: Kliničko iskustvo je jako ograničeno te sigurnost primjene lijeka LITAK u ovih bolesnika nije dobro utvrđena (vidjeti dijelove 4.3 i 5.2).
English: You may also receive an additional medicine containing the active substance allopurinol in order to reduce excess of uric acid.
Croatian: Možete dobiti i dodatni lijek koji sadrži alopurinol kao djelatnu tvar kako bi se smanjila suvišna količina mokraćne kiseline.
English: Skin rashes (2-31%) are mainly described in patients with other concomitantly administered medicinal products known to cause rash (antibiotics and/or allopurinol).
Croatian: Kožni osip (2-31%) uglavnom je opisan u bolesnika koji istovremeno uzimaju druge lijekove koji izazivaju osip (antibiotici i/ili alopurinol).
English: Increased resorptions, reduced live litter sizes, reduced foetal weights and increased foetal malformations of the head, trunk and appendages were seen at 3.0 mg/kg/day.
Croatian: Povećane resorpcije, smanjena veličina živog okota, smanjena težina ploda i povećane fetalne malformacije glave, trupa i ekstremiteta viđene su kod doze od 3,0 mg/kg/dan.
English: Forty percent of the patients who were treated with LITAK at a dose of 0.7 mg/kg body weight per cycle suffered from infections.
Croatian: Četrdeset posto bolesnika liječenih lijekom LITAK u dozi od 0,7 mg/kg tjelesne težine po ciklusu imalo je infekcije.
English: No cytotoxic effect of cladribine could be observed in cell lines of solid tumours.
Croatian: Citotoksičnost kladribina nije primijećena u staničnim linijama solidnih tumora.
English: Pack size of 1 or 5 vials.
Croatian: Veličine pakiranja su 1 ili 5 bočica.
English: For any information about this medicine, please contact the Marketing Authorisation Holder.
Croatian: Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje lijeka u promet
English: You must not use LITAK with other medicines that affect the production of blood cells in the bone marrow (myelosuppression).
Croatian: Ne smijete primjenjivati LITAK s drugim lijekovima koji utječu na stvaranje krvnih stanica u koštanoj srži (mijelosupresija).
English: Following cladribine, the incidence of second malignancies ranges from 0% to 9.5% after a median observation period of 2.8 to 8.5 years.
Croatian: Nakon liječenja kladribinom učestalost sekundarnih zloćudnih bolesti je u rasponu od 0% do 9,5% nakon medijana razdoblja promatranja od 2,8 do 8,5 godina.
English: These were on average more severe than the infections manifested in 27% of all patients receiving a reduced dose of 0.5 mg/kg body weight per cycle.
Croatian: Te su infekcije u prosjeku bile ozbiljnije od infekcija koje su se javile u 27% bolesnika koji su primali smanjenu dozu od 0,5 mg/kg tjelesne težine po ciklusu.
English: A daily oral dose of 100 mg of allopurinol is recommended for a period of 2 weeks.
Croatian: Preporučuje se dnevna oralna doza alopurinola od 100 mg tijekom 2 tjedna.
English: The cumulative frequencies of second malignancy are 5%, 10-12% and 13-14% following 5, 10 and 15 years respectively after diagnosis of hairy cell leukaemia.
Croatian: Kumulativna učestalost sekundarnih zloćudnih bolesti je 5%, 10-12% i 13-14%, nakon 5, 10, odnosno 15 godina nakon dijagnoze leukemije vlasastih stanica.
English: Due to the similar intracellular metabolism, cross-resistance with other nucleoside analogues, such as fludarabine or 2'-deoxycoformycin may occur.
Croatian: Uslijed sličnog unutarstaničnog metabolizma može se razviti križna rezistencija s drugim nukleozidnim analozima poput fludarabina ili 2'-deoksikoformicina.
English: Since interactions with medicinal products undergoing intracellular phosphorylation, such as antiviral agents, or with inhibitors of adenosine uptake may be expected, their concomitant use with cladribine is not recommended.
Croatian: Budući da se mogu očekivati interakcije s lijekovima koji podliježu unutarstaničnoj fosforilaciji, poput antivirusnih lijekova, ili s inhibitorima unosa adenozina, ne preporučuje se njihova primjena istovremeno s kladribinom.
English: Cladribine is moderately acutely toxic to mice, with an LD50 of 150 mg/kg by intraperitoneal administration.
Croatian: Kladribin je umjereno akutno toksičan za miševe, s LD50 od 150 mg/kg kod intraperitonealne primjene.
English: Patients who have received an overdose of cladribine should be monitored haematologically for at least four weeks.
Croatian: Bolesnike predozirane kladribinom treba hematološki pratiti najmanje četiri tjedna.
English: Forty-three percent of patients with hairy cell leukaemia experienced infectious complications at standard dose regimen.
Croatian: Četrdeset tri posto bolesnika s leukemijom vlasastih stanica imalo je infekcijske komplikacije kod standardnog režima doziranja.
English: Pharmacokinetic studies in humans showed that the plasma concentration curve of cladribine fits a 2or 3-compartment model with - and β-half-lives of on average 35 minutes and 6.7 hours, respectively.
Croatian: Farmakokinetička ispitivanja u ljudi pokazala su da krivulja koncentracije kladribina u plazmi odgovara modelu s dva ili tri odjeljka s poluživotom α u prosjeku 35 minuta i poluživotom β 6,7 sati.
English: 10 ml type I glass vial with rubber stopper (bromobutyl) and flip-off aluminium cap.
Croatian: Staklena bočica od 10 ml (staklo tip I) s gumenim čepom (bromobutil) i „flip-off“ aluminijskim zatvaračem.
English: Acute, irreversible neuro- and nephrotoxicity have been described in individual patients treated at a dose which was ≥ 4 times higher than the recommended regimen for hairy cell leukaemia.
Croatian: Akutna ireverzibilna neuro- i nefrotoksičnost opisane su u pojedinih bolesnika liječenih dozom koja je bila ≥4 viša od preporučenog režima doziranja za leukemiju vlasastih stanica.
English: Although anti-infective prophylaxis is not generally recommended, it may be beneficial for patients immunocompromised prior to therapy with cladribine or for patients with a pre-existing agranulocytosis.
Croatian: Premda se antiinfekcijska profilaksa općenito ne preporučuje, može se pokazati korisnom za bolesnike koji su imunokompromitirani prije liječenja kladribinom ili u bolesnika s već prisutnom agranulocitozom.
English: In case of infections, antibiotic treatment should be initiated as required.
Croatian: U slučaju infekcija treba započeti liječenje odgovarajućim antibiotikom.
English: Cladribine is eliminated mainly by the kidneys.
Croatian: Kladribin se eliminira uglavnom putem bubrega.
English: Furthermore, CdATP inhibits ribonucleotide reductase, the enzyme responsible for the conversion of ribonucleotides into deoxyribonucleotides.
Croatian: Nadalje, CdATP inhibira ribonukleotid-reduktazu koja je odgovorna za konverziju ribonukleotida u deoksiribonukleotide.
English: Due to a potential increase of haematological toxicity and bone marrow suppression, cladribine must not be used concomitantly with other myelosuppressive medicinal products.
Croatian: Uslijed mogućeg povećanja hematološke toksičnosti i supresije koštane srži, kladribin se ne smije uzimati istovremeno s drugim mijelosupresivnim lijekovima.
English: Patients undergoing treatment with cladribine should be closely monitored for signs of haematologic and non-haematologic toxicities.
Croatian: Bolesnike koji uzimaju kladribin treba pažljivo nadzirati zbog znakova hematološke i nehematološke toksičnosti.
English: Gastrointestinal adverse reactions like nausea (5-28%), vomiting (1-13%), and diarrhoea (3-12%) as well as fatigue (2-48%), headache (1-23%), and decreased appetite (1-22%) have been reported during treatment with cladribine.
Croatian: Tijekom liječenja kladribinom zabilježene su nuspojave probavnog sustava poput mučnine (5-28%), povraćanja (1-13%) i proljeva (3-12%), kao i umor (2-48%), glavobolja (1-23%) i smanjen apetit (1-22%).
English: Very common: infections * (e.g. pneumonia *, septicaemia *)
Croatian: Vrlo često: infekcije* (npr. pneumonija*, septikemija*)
English: Therapeutic risks and benefits should be carefully evaluated in patients with active or suspected infections.
Croatian: Rizike i koristi liječenja treba pažljivo procijeniti kod bolesnika s aktivnom infekcijom ili sumnjom na infekciju.
English: In another study using a dose of 0.10 mg/kg body weight/day, the maximum plasma concentration Cmax after continuous intravenous infusion was 5.1 ng/ml (tmax: 12 hours) compared to 51 ng/ml after subcutaneous bolus injection (tmax: 25 minutes).
Croatian: U drugom ispitivanju gdje je primijenjena doza od 0,10 mg/kg tjelesne težine/dan, vršna koncentracija u plazmi Cmax nakon kontinuirane intravenske infuzije bila je 5,1 ng/ml (tmax: 12 sati) u odnosu na 51 ng/ml nakon supkutane bolus injekcije (tmax: 25 minuta).
English: Do not use LITAK if you notice that the vial is damaged or that the solution is not clear or contains any particles.
Croatian: LITAK se ne smije upotrijebiti ako primijetite da je bočica oštećena ili da otopina nije bistra ili da sadrži čestice.
English: The highest incidence of second malignancy with LITAK was 6.5% after a median follow-up of 8.4 years.
Croatian: Najveća incidencija sekundarnih zloćudnih tvorbi kod primjene lijeka LITAK bila je 6,5% nakon medijana praćenja od 8,4 godine.
English: Cladribine is an antineoplastic and immunosuppressive substance that can induce considerable toxic adverse reactions, such as myelo- and immunosuppression, long-lasting lymphocytopenia, and opportunistic infections.
Croatian: Kladribin je antineoplastička i imunosupresivna tvar koja može izazvati znatne toksične nuspojave, poput mijelo- i imunosupresije, dugotrajne limfocitopenije i oportunističkih infekcija.
English: Suggested evaluation for PML includes neurology consultation, magnetic resonance imaging of the brain, and cerebrospinal fluid analysis for JC virus (JCV) DNA by polymerase chain reaction (PCR) or a brain biopsy with testing for JCV.
Croatian: Predložena dijagnostička obrada za utvrđivanje PML-a uključuje neurološki pregled, snimanje mozga magnetskom rezonancijom (MR), analizu cerebrospinalnog likvora na DNK JC virusa (JCV) metodom lančane reakcije polimerazom (engl. polymerase chain reaction, PCR) ili biopsijom mozga s testiranjem na JCV.
English: The mechanism of action of cladribine is attributed to the incorporation of CdATP into DNA strands: the synthesis of new DNA in dividing cells is blocked and the DNA repair mechanism is inhibited, resulting in an accumulation of DNA strand breaks and a decrease of NAD (nicotinamide adenine dinucleotide) and ATP concentration, even in resting cells.
Croatian: Mehanizam djelovanja kladribina pripisuje se ugradnji CdATP-a u lance DNK: sinteza nove DNK u stanicama koje se dijele je zaustavljena i mehanizam popravka DNK je inhibiran, što dovodi do nakupljanja prekida lanaca DNK i smanjenja koncentracije NAD-a (nikotinamid-adenin-dinukleotida) i ATP-a čak i u stanicama u mirovanju.
English: Pull slightly on the plunger to check that no blood vessel has been punctured.
Croatian: Blago povucite klip kako biste provjerili da krvna žila nije probijena.
English: Cladribine causes serious birth defects when administered during pregnancy.
Croatian: Kladribin uzrokuje ozbiljne kongenitalne malformacije ukoliko se primjenjuje tijekom trudnoće.
English: Date of first authorisation: 14/04/2004 Date of last renewal: 27/03/2009
Croatian: Datum posljednje obnove odobrenja: 27. ožujka 2009.
English: It is unknown whether cladribine is excreted in human milk.
Croatian: Nije poznato izlučuje li se kladribin u majčino mlijeko.
English: Common: tachycardia, heart murmur, hypotension, epistaxis, myocardial ischemia *
Croatian: Često: tahikardija, šum na srcu, hipotenzija, epistaksa, ishemija miokarda*
English: An accumulation of active CdATP is observed predominantly in cells with a high dCK activity and a low deoxynucleotidase activity, particularly in lymphocytes and in other haematopoietic cells.
Croatian: Nakupljanje aktivnog CdATP-a najviše je primijećeno u stanicama s visokom aktivnošću dCK i niskom aktivnošću deoksinukleotidaze, pogotovo u limfocitima i drugim hematopoetskim stanicama.
English: Corticosteroids have been shown to enhance the risk for severe infections when used in combination with cladribine and should not be given concomitantly with cladribine.
Croatian: Pokazalo se da kortikosteroidi povećavaju rizik od teških infekcija kada se primjenjuju u kombinaciji s kladribinom te se stoga ne smiju dati zajedno s kladribinom.
English: In rabbits, cladribine is teratogenic at doses of 3.0 mg/kg/day (given on gestation days 7-19).
Croatian: U zečeva je kladribin teratogen u dozi od 3,0 mg/kg/dan (primijenjen 7.-19. gestacijskog dana).
English: Careful and regular monitoring of peripheral blood counts is essential during, and for 2 to 4 months following, treatment with cladribine to detect potential adverse reactions and consequent complications (anaemia, neutropenia, thrombocytopenia, infections, haemolysis or bleedings), and to survey haematologic recovery.
Croatian: Pažljivo i redovito praćenje broja perifernih krvnih stanica neophodno je tijekom liječenja i 2 do 4 mjeseca nakon liječenja kladribinom, kako bi se otkrili mogući štetni učinci i posljedične komplikacije (anemija, neutropenija, trombocitopenija, infekcije, hemoliza ili krvarenja) te kako bi se pratio hematološki oporavak.
English: The effects of cladribine on fertility have not been studied in animals.
Croatian: Učinci kladribina na plodnost nisu ispitani na životinjama.
English: Remove the injection needle from the wrapping and place it firmly on the tip of the syringe.
Croatian: Izvadite injekcijsku iglu iz omota i učvrstite je na vrh štrcaljke.
English: The risk requires assessment on a case-by-case basis (see section 4.4).
Croatian: Rizik treba procjenjivati od slučaja do slučaja (vidjeti dio 4.2).
English: The recovery of cytotoxic T-lymphocytes and natural killer cells occurs within 3 to 12 months.
Croatian: Do oporavka citotoksičnih T limfocita i stanica ubojica dolazi za 3 do 12 mjeseci.
English: In 7- to 14-day continuous intravenous infusion studies in cynomolgus monkeys, the target organs were the immune system ( 0.3 mg/kg/day), bone marrow, skin, mucous membranes, nervous system and testes ( 0.6 mg/kg/day) and kidneys ( 1 mg/kg/day).
Croatian: Pri ispitivanjima 7-dnevne i 14-dnevne kontinuirane intravenske infuzije u makaki majmuna ciljni organi bili su imuni sustav (≥ 0,3 mg/kg/dan), koštana srž, koža, sluznice, živčani sustav i testisi (≥ 0,6 mg/kg/dan) te bubrezi (≥ 1 mg/kg/dan).
English: Packs contain 1 or 5 vials, each with 5 ml of solution.
Croatian: Pakiranje sadrži 1 ili 5 bočica, svaku s 5 ml otopine.
English: How to store LITAK
Croatian: Kako čuvati LITAK
English: Patients with active infection should be treated for the underlying condition prior to receiving therapy with cladribine.
Croatian: Bolesnike s aktivnom infekcijom potrebno je liječiti prije nego što prime terapiju kladribinom.
English: Culture-negative fever following treatment with cladribine occurs in 10-40% of patients with hairy cell leukaemia and is rarely observed in patients with other neoplastic disorders.
Croatian: Vrućica koja nije povezana s infekcijom javlja se u 10-40% bolesnika s leukemijom vlasastih stanica nakon liječenja kladribinom, a rijetko je primijećena u bolesnika s drugim neoplastičkim poremećajima.
English: What LITAK contains - The active substance is cladribine.
Croatian: Što LITAK sadrži - Djelatna tvar je kladribin.
English: Non-haematological adverse reactions are generally mild to moderate in severity.
Croatian: Nehematološke nuspojave uglavnom su blage do umjerene ozbiljnosti.
English: LITAK can be self-administered by the patient.
Croatian: Bolesnik može sam primjenjivati LITAK.
English: Uncommon: conjunctivitis Very rare: blepharitis
Croatian: Manje često: konjuktivitis Vrlo rijetko: blefaritis
English: The frequency of second malignancy following treatment with LITAK was 3.4% in all 232 hairy cell leukaemia patients treated, during a 10-year period.
Croatian: Učestalost sekundarnih zloćudnih tvorbi nakon liječenja lijekom LITAK bila je 3,4% u svih 232 liječenih bolesnika s leukemijom vlasastih stanica tijekom razdoblja od 10 godina.
English: The biexponential decline of the serum concentration of cladribine after subcutaneous bolus injection is comparable to elimination parameters after 2-hour intravenous infusion with an initial and terminal half-life of approximately 2 hours and 11 hours, respectively.
Croatian: Bieksponencijalno opadanje serumske koncentracije kladribina nakon potkožne bolus injekcije usporedivo je s eliminacijskim pokazateljima nakon dvosatne intravenske infuzije s početnim i terminalnim poluvremenom eliminacije od približno 2 odnosno 11 sati.
English: The cytotoxicity of cladribine is dose-dependent.
Croatian: Citotoksičnost kladribina ovisi o dozi.
English: Dispose the puncture-proof container as instructed by your doctor, nurse or pharmacist.
Croatian: Odložite spremnik prema uputama liječnika, medicinske sestre ili ljekarnika.
English: Cladribine shows complete bioavailability after parenteral administration; the mean area under the plasma concentration versus time curve (AUC) is comparable after continuous or intermittent 2-hour intravenous infusion and after subcutaneous injection.
Croatian: Kladribin pokazuje potpunu bioraspoloživost nakon parenteralne primjene; prosječna površina ispod krivulje koncentracije naspram vremena (AUC) nakon kontinuirane ili intermitentne dvosatne intravenske infuzije usporediva je s onom nakon supkutane injekcije.
English: Antineoplastic agents, such as cladribine, which interfere with DNA, RNA and protein synthesis, might be expected to have adverse effects on human gametogenesis (see section 5.3).
Croatian: Od antineoplastičkih lijekova, kao što je kladribin, koji ometaju sintezu DNK, RNK i proteina, može se očekivati da imaju štetne učinke na gametogenezu u ljudi (vidjeti dio 5.3).
English: In case you miss an injection of a dose, tell your doctor immediately.
Croatian: U slučaju da propustite ubrizgati dozu, odmah obavijestite liječnika.
English: - one vial of LITAK (or two vials if you need to inject more than 5 ml).
Croatian: Kako biste si sami dali potkožnu injekciju, potrebno Vam je: - jedna bočica lijeka LITAK (ili dvije bočice ako trebate ubrizgati više od 5 ml).
English: For all patients treated with LITAK, periodic assessment of renal and hepatic function is advised as clinically indicated.
Croatian: Za sve bolesnike koji primaju LITAK preporučuje se povremena provjera funkcije bubrega i jetre u skladu s kliničkim indikacijama.
English: An influence of cladribine on the activity of other antineoplastic agents has not been observed in vitro (e.g. doxorubicin, vincristine, cytarabine, cyclophosphamide) and in vivo.
Croatian: Nije primijećen utjecaj kladribina na djelovanje drugih antineoplastičkih lijekova niti in vitro (npr. doksorubicinom, vinkristinom, citarabinom, ciklofosfamidom) ni in vivo.
English: The mean plasma clearance amounts to 794 ml/min after intravenous infusion and to 814 ml/min after subcutaneous bolus injection at a dose of 0.10 mg/kg body weight/day.
Croatian: Prosječni klirens u plazmi iznosi 794 ml/min nakon intravenske infuzije i 814 ml/min nakon potkožne bolus injekcije kod doze od 0,10 mg/kg tjelesne težine/dan.
English: Remove the needle guard without touching the needle.
Croatian: Uklonite poklopac s igle bez dodirivanja igle.
English: Fever of unknown origin frequently occurs in patients treated for hairy cell leukaemia and is manifested predominantly during the first 4 weeks of therapy.
Croatian: Vrućica nepoznatog porijekla javlja se u bolesnika liječenih od leukemije vlasastih stanica te je najviše izražena tijekom prva 4 tjedna liječenja.
English: What LITAK looks like and contents of the pack LITAK is available in glass vials containing 5 ml of clear, colourless solution for injection.
Croatian: LITAK je dostupan u staklenim bočicama koje sadrže 5 ml bistre, bezbojne otopine za injekciju.